Novocure launches pivotal ovarian cancer trial

Novocure (NSDQ:NVCR) said today that it kicked off a Phase 3 pivotal trial testing its Tumor Treating Fields therapy combined with paclitaxel in people with recurrent, platinum-resistant ovarian cancer.
The 540-patient trial has a primary endpoint of overall survival, with secondary endpoints that include progression-free survival, objective response rate, severity and frequency of adverse events and quality of life.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure launches pivotal ovarian cancer trial appeared first on MassDevice.

Source: Mass Device - March 22, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news